Literature DB >> 2785147

Host and bacterial factors associated with Haemophilus influenzae type b disease in Minnesota children vaccinated with type b polysaccharide vaccine.

D M Granoff1, K Sheetz, J P Pandey, M H Nahm, J H Rambeck, J L Jacobs, J Musser, R K Selander, M Kabeer, T V Murphy.   

Abstract

Host and bacterial factors were evaluated among 86 Minnesota children with Haemophilus influenzae type b disease detected by active surveillance after introduction of type b polysaccharide vaccine in the state. Children were 2-6 y of age. Thirty-three (38%) had been vaccinated. There was no significant difference between the frequency of low serum concentrations of IgM, IgA, IgG, or IgG2 in the vaccinated and nonvaccinated subjects (13% vs. 8%, P = .5). The presence of the Gm immunoglobulin allotype phenotype (1,3,17;23;5,13,21), previously associated with a lower relative risk of vaccine failure in children from other states, was associated with a fourfold decrease in the relative risk of vaccine failure in Minnesota (P less than .07). Haemophilus isolates from 58 of the children were available for clonal characterization by multilocus electrophoresis and outer membrane protein subtyping. There were no significant differences between the clone distribution of the strains causing disease in vaccinated and nonvaccinated patients, and nearly all disease-producing clones in Minnesota also are known to cause disease in other areas of the country. Thus, vaccine failure in Minnesota is infrequently associated with hypogammaglobulinemia or with infection by unusual clones of a H. influenzae type b. Also, the Gm phenotype associated with protection against vaccine failure in other areas of the USA appears to be protective in Minnesota.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785147     DOI: 10.1093/infdis/159.5.908

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Effectiveness of Haemophilus influenzae type b vaccines.

Authors:  D M Stieb; H H Frayha; A D Oxman; H S Shannon; B G Hutchison; F S Crombie
Journal:  CMAJ       Date:  1990-04-01       Impact factor: 8.262

2.  Molecular characteristics of Haemophilus influenzae causing invasive disease during the period of vaccination in Switzerland: analysis of strains isolated between 1986 and 1993.

Authors:  K Muhlemann; M Balz; S Aebi; K Schopfer
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Major subtypes of invasive Haemophilus influenzae from 1983 to 1985 in Atlanta, Ga.

Authors:  J A Elliott; N Pigott; S L Cochi; R R Facklam
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

4.  Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n).

Authors:  P J Späth; A G Sjöholm; G N Fredrikson; G Misiano; R Scherz; U B Schaad; B Uhring-Lambert; G Hauptmann; J Westberg; M Uhlén; C Wadelius; L Truedsson
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

5.  Genomic DNA fingerprints and phenotypic characteristics of serotype B Haemophilus influenzae isolates from Italy.

Authors:  M Mencarelli; C Marsili; A Zanchi; C Pantini; C Cellesi
Journal:  Eur J Epidemiol       Date:  1993-07       Impact factor: 8.082

Review 6.  Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy.

Authors:  R de Groot; G Dzoljic-Danilovic; B van Klingeren; W H Goessens; H J Neyens
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

7.  Nontypeable Haemophilus influenzae: pathogenesis and prevention.

Authors:  A R Foxwell; J M Kyd; A W Cripps
Journal:  Microbiol Mol Biol Rev       Date:  1998-06       Impact factor: 11.056

8.  Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.

Authors:  T Pressler; J P Pandey; F Espersen; S S Pedersen; A Fomsgaard; C Koch; N Høiby
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.